Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01689766 · ClinicalTrials.gov registry record · Phase 2
Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma
A Phase 2 study of Metastatic Renal Cell Carcinoma, sponsored by Endocyte.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 2
- Study locations
NCT01689766: Completed Phase 2 study of Metastatic Renal Cell Carcinoma, sponsored by Endocyte.
NCT01689766 is a Phase 2 study of Metastatic Renal Cell Carcinoma that has completed, run by Endocyte. The registered enrollment target is 150 participants, roughly in line with the 139-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01689766, a Phase 2 study of Metastatic Renal Cell Carcinoma, has completed, sponsored by Endocyte.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
Phase 2, multi-center, open-label, single-treatment group, baseline-controlled study to identify subjects with Folate Receptor-Positive Metastatic Renal Cell Carcinoma
Conditions Studied
Interventions
- DRUG Technetium Tc 99m EC20
Study Locations (2)
Minnesota
- Mayo Clinic - Rochester
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2003-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01689766
The ClinicalTrials.gov registry entry for NCT01689766 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 139-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target. The listed sponsor is Endocyte, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Technetium Tc 99m EC20 is the first listed.
NCT01689766 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Texas.
Frequently Asked Questions
What is clinical trial NCT01689766 about?
NCT01689766 is a clinical study titled "Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma". Phase 2, multi-center, open-label, single-treatment group, baseline-controlled study to identify subjects with Folate Receptor-Positive Metastatic Renal Cell Carcinoma
What is the current status of trial NCT01689766?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2003-11.
What conditions does trial NCT01689766 study?
This clinical trial studies the following conditions: Metastatic Renal Cell Carcinoma.
What interventions are being tested in trial NCT01689766?
The interventions under investigation include: Technetium Tc 99m EC20 (DRUG).
Who is sponsoring clinical trial NCT01689766?
This trial is sponsored by Endocyte, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01689766 being conducted?
This trial has 2 study locations across Minnesota, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
RECRUITING · Phase 2
-
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RECRUITING · Phase 2
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
-
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.